Allon Secures SPA for Tau Drug Davunetide Phase III
By Catherine Shaffer
Wednesday, January 5, 2011
Allon Therapeutics Inc. said the FDA agreed to a special protocol assessment (SPA) for its drug candidate davunetide in progressive supranuclear palsy.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.